tiprankstipranks
Intellia Therapeutics price target lowered to $70 from $80 at Wells Fargo
The Fly

Intellia Therapeutics price target lowered to $70 from $80 at Wells Fargo

Wells Fargo lowered the firm’s price target on Intellia Therapeutics (NTLA) to $70 from $80 and keeps an Overweight rating on the shares. The firm notes that Phase 1 ATTR-CM data for nex-z compare well vs. historical data shown by silencers and stabilizers, despite having a greater proportion of patients with more severe disease. Wells thinks this should bode well for Phase 3 success.

Pick the best stocks and maximize your portfolio:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App